IceCure Medical announced it has filed a 510 submission with the FDA for clearance of its next-generation single probe cryoablation system, the XSense System and cryoprobes. The filing contains a request for clearance for all of the indications for which ProSense has already received the requisite FDA clearance, including general minimally invasive cryoablation applications for the kidney, liver, fibroadenomas and neurology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical price target raised to $2.90 from $1.90 at Alliance Global Partners
- IceCure Medical Triumphs in Breast Cancer Study
- IceCure Medical’ reports positive topline results for breast tumor cryoablation
- IceCure Medical receives Notice of Allowance from Japan Patent Office
- IceCure Medical announces new preliminary data on ProSense
